Optimer Pharmaceuticals, Inc. Reports Positive Data from its North American Phase 3 CDI Study of OPT-80

SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today released positive top-line results from a pivotal Phase 3 clinical study of the Company’s lead anti-infective drug candidate, OPT-80, in patients with Clostridium difficile Infection (CDI).